CA-ALKIRA,-INC.
Network Cloud pioneer Alkira® today announced a close collaboration with the Microsoft for Startups program, a select group of emerging businesses hand-picked by Microsoft for the benefits they offer to Microsoft Azure customers in their journey to the cloud. The select start-ups receive growth partnership and ecosystem support from Microsoft including access to technical, sales and marketing opportunities and leadership. Alkira also announced that the Alkira Cloud Services Exchange (CSX) – the core of the company’s Network Cloud platform – is now available on the Azure Marketplace.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005521/en/
The Alkira Network Cloud platform which reduces the time, cost and complexity of connectivity cloud environments, provides Azure customers with increased performance, manageability and security when deploying Windows workloads in the Azure cloud. Microsoft Azure customers can access Alkira’s solution in Azure, or in a multi-cloud network alongside other best-of-breed products in the Azure Marketplace.
Benefitting from the underlying power of Azure, Alkira CSX is delivered as a secure cloud networking infrastructure as-a-service that dynamically scales according to customers’ needs and reduces the time taken to deploy cloud networks from months to minutes.
Amir Khan, Chief Executive Officer and Founder of Alkira, said: “The time, cost and complexity of building networks in the cloud with end-to-end security and management visibility are major challenges holding back digital transformation. Our service was developed to help businesses overcome the trade-offs, complexity and long lead times associated with cloud networking. The Alkira Network Cloud platform accelerates the deployment and simplifies the management of cloud workloads, leaving customers free to focus on the objectives of their business. We’re excited to be deepening our relationship with Microsoft through the Microsoft for Startups program and to be able to offer those benefits to the growing number of organizations seeking transformational solutions from the Azure Marketplace.”
Jeff Ma, General Manager of Microsoft for Startups, commented: “Our start-up program gives new businesses access to the incredible resources of Microsoft and helps to bring the benefits of exciting new technologies like Alkira’s Network Cloud platform to Microsoft’s Azure customers. Alkira’s platform provides a powerful and flexible set of capabilities to leverage the power of Azure to deploy fully featured cloud networks.”
Mamoon Hamid, Partner at Kleiner Perkins added: “It’s time for the network to join the cloud era, and Alkira’s Cloud Networking Infrastructure as-a-Service provides customers a secure, simplified path to the Microsoft Azure cloud. Microsoft is progressively offering companies like Alkira the opportunity to help Azure customers on their cloud journey, and we're already seeing it unlock value for everyone involved."
Brad Casemore, Research Vice President, Datacenter Networks at IDC said: “IDC finds that enterprises are gaining greater appreciation of how modern infrastructure can support strategic cloud objectives such as business agility, application experience, robust security. That said, while enterprise architects want to help their organizations achieve greater business agility through the migration of workloads to cloud, they also want to ensure that the transition doesn’t entail compromises to operational control and management. Alkira’s Network Cloud platform addresses these requirements by helping organizations and their architects reconcile the business benefits of cloud with the need for effective control.”
Microsoft customers who access Alkira’s Network Cloud through Azure Marketplace benefit from reduced procurement overheads, simplified billing and quicker deployment, as well as the assurance of Microsoft certification.
For more information:
- Read Amir Khan’s blog on teaming with Microsoft
- Download an Alkira in Azure Cloud white paper
About Alkira
Alkira® developed the Network Cloud which enables Enterprises to build and deploy a global unified Cloud Network Infrastructure as-a-Service (CNaaS) that delivers network connectivity, advanced network and services, and end-to-end visibility and governance. Alkira Cloud Services Exchange™ (CSX) seamlessly and securely connects branches, data centers, remote users and clouds. Alkira was founded by CEO Amir Khan, founder and former CEO of Viptela, and Atif Khan, CTO, former VP of Integrated Solutions and a member of the Viptela founding team. Alkira has raised $76M from Sequoia Capital, Kleiner Perkins, Koch Disruptive Technologies, LLC, and GV Capital (formerly Google Ventures). Learn more at www.Alkira.com or follow us @AlkiraNet
Alkira® is a registered trademark and Alkira Cloud Services Exchange™ is a trademark of Alkira, Inc. All other marks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005521/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom